Society · Health · June 17, 2026

People on Ozempic Lose Weight. A New Study Says They Also Start Moving Less.

Doctors have long assumed that as patients shed weight on GLP-1 drugs like Ozempicand Wegovy, they’d naturally become more active. A new analysis presented at the Endocrine Society’s ENDO 2026 meeting suggests the opposite: people who started a GLP-1 actually moved lessafterward — fewer daily steps and less moderate-to-vigorous exercise.

Using fitness-tracker data from 753 adults with obesity, researchers found average daily steps fell from about 5,047 to 4,487, and moderate-to-vigorous activity dropped from roughly 28 to 22 minutes a day. The “major mistake” the coverage warns about isn’t the drug — it’s treating exercise as optional while on it, because GLP-1s strip away muscle along with fat.

Two caveats up front, in the interest of getting the science right. This is preliminaryconference data — presented as an abstract, not yet peer-reviewed or published in a journal. And the muscle-loss warning is context supplied by physicians, not something this particular study measured; what it measured is the drop in movement. With those guardrails, here is what the research found and why clinicians say it matters.

5,047 → 4,487 — average daily steps before vs. after starting a GLP-1 — a drop of ~560 steps a day · Source: Endocrine Society (ENDO 2026)
28 → 22 min — moderate-to-vigorous daily activity before vs. after — down nearly 6 minutes a day · Source: Endocrine Society; ScienceDaily
753 adults — obesity patients with sufficient Fitbit data, drawn from the NIH 'All of Us' research program linking wearables to health records · Source: Endocrine Society
Preliminary — the findings were presented as an abstract at ENDO 2026, not yet peer-reviewed or published — treat as early data · Source: Healio; Endocrine Society
Men hit hardest — the steepest activity declines were among men and patients with joint or muscle pain · Source: Endocrine Society

§ 01 / What the Study Found

The work, led by Dr. Sajana Maharjanof HSHS St. John’s Hospital in Springfield, Illinois, was a retrospective look at people before and after they started a GLP-1, using their own Fitbit data linked to electronic health records through the NIH’s All of Usprogram. Across 753 adults with obesity, both daily steps and moderate-to-vigorous activity fell after the medication began — the reverse of what most clinicians expected. Researchers described it as one of the first large looks at wearable-tracker data in GLP-1 users.

Keep Reading

Society · Education

A Denver Teacher Made Students Kiss in Class Skits and Graded Them. The Board Fired Her, 7–0.

Read →

KVUE — Experts say exercise is critical for GLP-1 users' muscles

§ 02 / Why Moving Less Is a Problem

Here is the physicians’ concern — and it’s context around the study, not a finding of it. GLP-1 drugs cause people to lose lean mass (muscle) along with fat; prior literature commonly estimates that a meaningful share of GLP-1 weight loss comes from lean tissue. If patients also cut their activity at the same time, they compound the hit to muscle, bone density, and metabolic health. That is why Maharjan framed the takeaway bluntly:

“While many assume that weight loss leads naturally to increased physical activity, our study suggests otherwise. The findings reinforce that exercise cannot be optional for people taking these medications.”
Dr. Sajana Maharjan · study lead · Endocrine Society / ENDO 2026

Cartoon satire: a downward step-count line chart on a fitness tracker beside a shrinking muscle-arm icon labeled 'lean mass' — The study measured the drop in movement. The muscle-loss risk is the reason doctors say that drop matters — fewer steps plus a drug that erodes lean mass is a bad combination.

§ 03 / The Fix — and the Counter-Evidence

The remedy clinicians point to is straightforward and not new: pair GLP-1 treatment with resistance (strength) training a few times a week and adequate protein to preserve muscle while the fat comes off. Walking more, rather than less, helps too. The behavioral finding here is a reminder that the drug does the weight loss but not the conditioning — the patient still has to.

For balance: not all recent research paints the muscle picture as catastrophic. A separate line of 2026 reporting and studies suggests GLP-1 muscle loss may be less severe than early alarm implied, and that newer drugs and add-on therapies may better preserve lean mass. The honest read is that the muscle question is still being worked out — while the practical advice (keep moving, lift, eat protein) holds regardless.

What Clinicians Recommend

Resistance training: strength work several times a week to protect muscle while losing fat.

Protein: enough daily protein to support lean mass during rapid weight loss.

Keep stepping: the study’s warning is that activity tends to fall on its own — so it has to be deliberate.

Keep Reading

Society · Crime Problem

The FBI Says It Stopped an Explosive-Drone Plot Against the White House UFC Event

Read →

CBS News — What to know about GLP-1 drugs and muscle loss

Cartoon satire: a balance scale weighing a GLP-1 injection pen against a dumbbell and protein plate, a doctor pointing to the dumbbell side, sign reading 'exercise not optional' — The drug handles the weight loss; it does not build or protect muscle. That, doctors say, is the patient's job — and the study suggests too many are skipping it.

§ 04 / The Bottom Line

GLP-1 drugs are a genuine breakthrough for obesity, and nothing here argues against taking them. The useful, if preliminary, finding is counterintuitive: the people most in need of preserving muscle as they lose weight appear to be exercising less, not more, once the drug takes over. The science on how much muscle is at stake is still maturing — but the advice doesn’t depend on settling that debate. On a GLP-1, movement isn’t the thing you can let slide; it’s the thing that makes the weight loss worth having.

WDIV Local 4 — GLP-1 weight-loss drugs can cause muscle loss without proper diet and exercise